Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pramipexole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 known ✓ | P35462 | 5/20 | 0.97 |
| ▸ | DRD2 known ✓ | P14416 | 5/20 | 0.97 |
| ▸ | DRD4 known ✓ | P21917 | 2/20 | 0.97 |
| ▸ | HRH2 | P25021 | 2/20 | 0.97 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.97 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.97 |
| ▸ | HTR1A | P08908 | 1/20 | 0.97 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.97 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.97 |
| ▸ | HTR1B | P28222 | 1/20 | 0.97 |
| ▸ | HTR2A | P28223 | 1/20 | 0.97 |
| ▸ | HTR7 | P34969 | 1/20 | 0.97 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.97 |
| ▸ | HRH1 | P35367 | 1/20 | 0.97 |
| ▸ | HTR2B | P41595 | 1/20 | 0.97 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.97 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.97 |
| ▸ | SCN3A | Q9NY46 | 5/20 | 0.55 |
| ▸ | SCN4A | P35499 | 4/20 | 0.55 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pramipexole SCHEMBL1132425 | 1.00 | DRD3 (0.97) | DRD3DRD2DRD4HRH2ADRA2A | |
| Pramipexole SCHEMBL3102892 | 1.00 | DRD3 (0.97) | DRD3DRD2DRD4HRH2ADRA2A | |
| Pramipexole SCHEMBL28361114 | 0.99 | DRD3 (1.00) | DRD3DRD2DRD4HRH2ADRA2A | |
| Pramipexole SCHEMBL22165339 | 0.99 | DRD3 (1.00) | DRD3DRD2DRD4HRH2ADRA2A | |
| Pramipexole SCHEMBL28506481 | 0.99 | DRD3 (1.00) | DRD3DRD2DRD4HRH2ADRA2A | |
| Pramipexole SCHEMBL2048695 | 0.99 | DRD3 (1.00) | DRD3DRD2DRD4HRH2ADRA2A | |
| Pramipexole SCHEMBL743891 | 0.99 | DRD3 (1.00) | DRD3DRD2DRD4HRH2ADRA2A | |
| Dexpramipexole SCHEMBL2289178 | 0.99 | DRD3 (1.00) | DRD3DRD2DRD4HRH2ADRA2A | |
| Pramipexole SCHEMBL153875 | 0.99 | DRD3 (1.00) | DRD3DRD2DRD4HRH2ADRA2A | |
| Pramipexole SCHEMBL28345162 | 0.99 | DRD3 (1.00) | DRD3DRD2DRD4HRH2ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11547700-B2 | Compositions and methods for treating synucleinopathies | CHASE THERAPEUTICS CORPORATION (US) | 2023-01-10 | — | — | US | disclosed |
| US-11318122-B2 | Pharmaceutical combination and its use for treating synucleinopathties | CHASE THERAPEUTICS CORPORATION (US) | 2022-05-03 | — | — | US | disclosed |
| US-11160809-B2 | NK1-antagonist combination and method for treating synucleinopathies | CHASE THERAPEUTICS CORPORATION (US) | 2021-11-02 | — | — | US | disclosed |
| CN-113329747-A | Domperidone compositions and methods for treating depression | 才思治疗公司 | 2021-08-31 | — | — | CN | disclosed |
| US-20200397761-A1 | COMPOSITIONS AND METHODS FOR TREATING SYNUCLEINOPATHIES | CHASE THERAPEUTICS CORPORATION (US) | 2020-12-24 | — | — | US | disclosed |
| US-20200375956-A1 | PHARMACEUTICAL COMBINATION AND ITS USE FOR TREATING SYNUCLEINOPATHIES | CHASE THERAPEUTICS CORPORATION (US) | 2020-12-03 | — | — | US | disclosed |
| US-10799484-B2 | Compositions and methods for treating synucleinopathies | CHASE THERAPEUTICS CORPORATION | 2020-10-13 | — | — | US | disclosed |
| US-20200147097-A1 | NK1-ANTAGONIST COMBINATION AND METHOD FOR TREATING SYNUCLEINOPATHIES | CHASE THERAPEUTICS CORPORATION (US) | 2020-05-14 | — | — | US | disclosed |
| EP-3609578-A1 | PHARMACEUTICAL COMBINATION AND ITS USE FOR TREATING SYNUCLEINOPATHIES | Chase Therapeutics Corporation (US) | 2020-02-19 | — | — | EP | disclosed |
| EP-3609495-A1 | NK1-ANTAGONIST COMBINATION AND METHOD FOR TREATING SYNUCLEINOPATHIES | Chase Therapeutics Corporation (US) | 2020-02-19 | — | — | EP | disclosed |
| EP-3600291-A1 | COMPOSITIONS AND METHODS FOR TREATING SYNUCLEINOPATHIES | Chase Therapeutics Corporation (US) | 2020-02-05 | — | — | EP | disclosed |
| CN-110730662-A | NK 1-antagonist combinations and methods for treating synucleinopathies | 才思治疗公司 | 2020-01-24 | — | — | CN | disclosed |
| CN-110662537-A | Compositions and methods for treating synucleinopathies | 才思治疗公司 | 2020-01-07 | — | — | CN | disclosed |
| WO-2018191408-A1 | PHARMACEUTICAL COMBINATION AND ITS USE FOR TREATING SYNUCLEINOPATHIES | CHASE THERAPEUTICS CORPORATION (US) | 2018-10-18 | — | — | WO | disclosed |
| WO-2018191160-A1 | NK1-ANTAGONIST COMBINATION AND METHOD FOR TREATING SYNUCLEINOPATHIES | CHASE THERAPEUTICS CORPORATION (US) | 2018-10-18 | — | — | WO | disclosed |
| WO-2018183192-A1 | COMPOSITIONS AND METHODS FOR TREATING SYNUCLEINOPATHIES | CHASE THERAPEUTICS CORPORATION (US) | 2018-10-04 | — | — | WO | disclosed |